Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Patients with OA Respond to Low-Dose SoluMatrix Meloxicam; Off-Label Use of Ketoconazole Results in Death

  |  

Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Iroko Pharmaceuticals LLC. News release: New data shows that Vivlodex reduces rescue medication use in patients with osteoarthritis pain. 2016 May 12.
  2. Altman R, Gibofsky A, Kivitz A, et al. A novel application of the medication event monitoring system (MEM) to track rescue medication use in a phase 3 study of low-dose SoluMatrix meloxicam in patients with osteoarthritis (OA) pain. J Pain. 2016;17(4): Suppl S70. Abstract 380.
  3. S. Food and Drug Administration. Safety alert: Nizoral (ketoconazole) oral tablets: Drug safety communication—prescribing for unapproved uses, including skin and nail infections continues; linked to patient death. 2016 May 19.

Related Articles

    FDA Approves New Drugs for Pain

    FDA Updates Belbuca, buccal-administered buprenorphine, has received U.S. Food and Drug Administration (FDA) approval for treating severe chronic pain.1 The dosage form is a dissolving film that is absorbed through the inner lining of the cheek for chronic pain management. It’s expected to be commercially available in the first quarter of 2016. Seven dosage strengths…

    Pain Treatments Move Closer to U.S. Market

    Two pain treatments, extended-release injectable suspension triamcinolone acetonide (Zilretta) and meloxicam, have seen movement at the U.S. Food and Drug Administration (FDA). In October, the agency approved Zilretta to treat osteoarthritis (OA) knee pain and accepted a new drug application for meloxicam to treat pain. FDA Approves Zilretta On Oct. 6, the FDA approved extended-release,…